The endogenous catecholamines (dopamine, norepinephrine (NE), and epinephrine (Epi)) share a common biosynthetic pathway and are inactivated by the same enzymatic systems. Understanding this biochemistry is essential for predicting how drugs that interfere with synthesis, release, reuptake, or catabolism alter catecholamine pharmacology. It also explains the severe drug interactions that arise when these pathways are pharmacologically blocked or overwhelmed.
Biosynthesis. Catecholamine synthesis begins with the amino acid tyrosine. The rate-limiting step is hydroxylation of tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA) by the enzyme tyrosine hydroxylase (TH), which requires molecular oxygen and tetrahydrobiopterin (BH4) as a cofactor. TH is subject to end-product inhibition by catecholamines themselves, providing autoregulation of synthesis. L-DOPA is then decarboxylated to dopamine by aromatic L-amino acid decarboxylase (DOPA decarboxylase), which requires pyridoxal phosphate (vitamin B6) as a cofactor. In dopaminergic neurons, synthesis ends here; in noradrenergic neurons, dopamine is transported into vesicles and converted to norepinephrine by dopamine beta-hydroxylase (DBH), which requires ascorbic acid (vitamin C) and copper. In the adrenal medulla, norepinephrine is methylated to epinephrine by phenylethanolamine N-methyltransferase (PNMT), using S-adenosylmethionine (SAM) as the methyl donor. PNMT expression is induced by glucocorticoids from the adjacent adrenal cortex, explaining why adrenal chromaffin cells primarily produce epinephrine.1
Vesicular Storage and Release. Catecholamines synthesized in the cytoplasm are transported into storage vesicles by the vesicular monoamine transporter isoform 2 (VMAT2), which exchanges two protons for one catecholamine molecule, driven by the proton gradient maintained by vacuolar adenosine triphosphatase (V-ATPase). Within the vesicle, catecholamines are sequestered at high concentration (up to 0.5 M) in a complex with adenosine triphosphate (ATP) and chromogranins, which protects them from oxidative degradation and cytoplasmic monoamine oxidase (MAO). Neuronal depolarization triggers calcium-dependent exocytosis, releasing catecholamines into the synapse or, in the case of the adrenal medulla, into the bloodstream. Reserpine and tetrabenazine block VMAT2, preventing vesicular uptake and depleting catecholamine stores.1
Reuptake and Inactivation. The primary mechanism for terminating catecholamine action at the synapse is reuptake via the norepinephrine transporter (NET), a sodium-dependent transporter on the presynaptic membrane. NET transports both norepinephrine and epinephrine back into the nerve terminal (uptake-1); dopamine transporter (DAT) performs the analogous function for dopamine. Within the nerve terminal, recaptured catecholamines may be re-packaged into vesicles or oxidized by MAO. Two MAO isoforms exist: monoamine oxidase type A (MAO-A), which preferentially oxidizes norepinephrine, epinephrine, and serotonin; and monoamine oxidase type B (MAO-B), which preferentially oxidizes dopamine and phenylethylamine. Both isoforms convert catecholamines to their aldehyde intermediates, which are further oxidized to their corresponding acids (vanillylmandelic acid (VMA) for epinephrine/norepinephrine; homovanillic acid (HVA) for dopamine). The second catabolic enzyme is catechol-O-methyltransferase (COMT), a cytosolic and membrane-bound enzyme that methylates the 3-hydroxyl group of the catechol ring using SAM as the methyl donor. COMT acts primarily in the liver, kidney, and gut rather than at the synapse, and is more important for inactivating circulating catecholamines than for synaptic termination.2
Absorption, Distribution, Metabolism, and Excretion (ADME) of the Catecholamine Class. The pharmacokinetic properties of the catecholamines as administered drugs are determined by their structural features. All catecholamines are poorly absorbed orally because of extensive first-pass metabolism by MAO and COMT in the gut wall and liver, and because of their hydrophilic character and susceptibility to oxidation at low gastric pH. Epinephrine and norepinephrine are therefore administered intravenously or via subcutaneous or intramuscular (IM) injection for systemic effects. Following intravenous administration, plasma half-lives are extremely short, typically 1 to 3 minutes for epinephrine and norepinephrine, due to rapid reuptake by NET, enzymatic inactivation by MAO and COMT, and uptake by non-neuronal tissues (uptake-2). Distribution volumes are moderate; the drugs do not cross the blood-brain barrier (BBB) significantly because the catechol structure makes them substrates for organic cation transporters that actively exclude them from the central nervous system (CNS). Dopamine and dobutamine are similarly restricted to parenteral administration. All catecholamines are excreted primarily as their methylated and/or oxidized metabolites in the urine; measurement of urinary VMA, HVA, and fractionated catecholamines is the basis for laboratory diagnosis of pheochromocytoma and paraganglioma.23
Tyrosine → L-DOPA: tyrosine hydroxylase (TH), rate-limiting step, requires tetrahydrobiopterin (BH4). L-DOPA → Dopamine: DOPA decarboxylase, requires vitamin B6. Dopamine → NE: dopamine beta-hydroxylase (DBH), requires vitamin C and copper. NE → Epi: phenylethanolamine N-methyltransferase (PNMT), requires SAM; induced by glucocorticoids in adrenal medulla. Catabolism: MAO (intraneuronal; MAO-A oxidizes NE/Epi; MAO-B oxidizes dopamine) and COMT (extraneuronal; liver, gut, kidney).
Epinephrine is the endogenous hormone of the acute stress response, synthesized and released by the adrenal medulla in response to fear, hypoglycemia, exercise, and physiological emergencies. It is the most pharmacologically versatile of the catecholamines, activating all five adrenergic receptor subtypes and producing effects that shift qualitatively with dose. Its clinical applications span anaphylaxis, cardiac arrest, bronchospasm, local anesthetic adjuvancy, and glaucoma, making it one of the most broadly used drugs in emergency medicine.
Receptor Profile. Epinephrine is a full agonist at alpha-1 (α1), alpha-2 (α2), beta-1 (β1), beta-2 (β2), and beta-3 (β3) adrenergic receptors. It has approximately equal potency at α and β receptors at clinical doses, but the predominant effect at any given dose depends on the relative receptor densities in target organs and on dose-dependent changes in plasma concentration. At low infusion rates, β2-mediated vasodilation in skeletal muscle vasculature predominates over α1-mediated vasoconstriction, reducing systemic vascular resistance (SVR). At higher doses or during bolus injection (as in anaphylaxis), α1 activation dominates in most vascular beds, producing net vasoconstriction and elevated mean arterial pressure (MAP). This dose dependence is clinically relevant: the epinephrine infusion dose required to treat anaphylactic shock (0.05 to 0.5 mcg/kg/min) differs substantially from the dose used to address cardiac arrest (1 mg IV every 3 to 5 minutes).4
Cardiovascular Pharmacology. The cardiovascular effects of epinephrine are the composite of cardiac stimulation and dose-dependent vascular effects. Myocardial β1 receptor activation increases heart rate, contractility, conduction velocity, and automaticity. At low doses, β2-mediated vasodilation in skeletal muscle vasculature lowers total peripheral resistance, so cardiac output rises but MAP may remain stable or fall slightly. At higher doses, α1-mediated vasoconstriction increases SVR and diastolic pressure. Pulse pressure widens because systolic pressure rises (from increased cardiac output) while diastolic pressure changes less predictably depending on the balance of β2 vasodilation and α1 vasoconstriction. Epinephrine increases myocardial oxygen demand substantially through combined increases in rate, contractility, and afterload, which limits its usefulness in patients with ischemic heart disease outside of life-threatening emergencies. The drug also increases automaticity of ectopic pacemakers, lowering the threshold for ventricular arrhythmias, an effect that is magnified in the setting of hypoxia, acidosis, and volatile anesthetics.4
Anaphylaxis. Epinephrine is the first-line, life-saving treatment for anaphylaxis, with no absolute contraindications in that setting. The rationale for its use addresses multiple simultaneous mechanisms of anaphylactic pathophysiology. Alpha-1 receptor activation reverses the vasodilation and vascular permeability that produce hypotension and angioedema; beta-1 activation supports cardiac output in the setting of distributive shock; beta-2 activation reverses bronchoconstriction; and beta-2 activation on mast cells and basophils inhibits further mediator release, blunting the ongoing allergic response. The recommended route is intramuscular injection into the mid-anterolateral thigh (vastus lateralis muscle) at a dose of 0.3 to 0.5 mg of the 1:1000 (1 mg/mL) solution in adults, or 0.01 mg/kg in children up to a maximum of 0.5 mg. The thigh is preferred over the deltoid because higher peak plasma concentrations are achieved more rapidly. Subcutaneous injection produces slower, less reliable absorption. Intravenous epinephrine for anaphylaxis is reserved for patients in cardiac arrest or profound, refractory shock with hemodynamic monitoring, as IV bolus epinephrine in an awake patient can precipitate severe hypertension, myocardial ischemia, or arrhythmias.5
Cardiac Arrest. During cardiopulmonary resuscitation (CPR), epinephrine is administered intravenously at 1 mg every 3 to 5 minutes. The mechanism during cardiac arrest is primarily α1-mediated vasoconstriction, which increases aortic diastolic pressure and thereby coronary perfusion pressure during the compression phase of CPR. The β1-mediated cardiac stimulation is of secondary benefit during arrest itself (the heart is fibrillating or asystolic) but becomes relevant for sustaining output after return of spontaneous circulation (ROSC). The evidence base for epinephrine in cardiac arrest has become considerably more nuanced: the landmark PARAMEDIC2 (Prehospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug Administration in Cardiac Arrest) trial (2018) showed that epinephrine increased ROSC and survival to hospital discharge but did not improve neurologically favorable survival at 30 days, and was associated with a higher rate of severe neurological injury among survivors. This finding has shifted the framing of epinephrine in cardiac arrest from an unqualified benefit to a drug that increases short-term survival at the potential cost of neurological outcome.6
Other Clinical Uses. Epinephrine is added to local anesthetic solutions at concentrations of 1:100,000 to 1:200,000 (5 to 10 mcg/mL) to produce local vasoconstriction via α1 receptors. This reduces systemic absorption of the local anesthetic (prolonging its duration of action and reducing peak plasma concentration), reduces bleeding at the surgical field, and decreases the risk of local anesthetic systemic toxicity (LAST). Epinephrine is contraindicated as a local anesthetic additive in digital blocks and other end-artery anatomical locations (penis, nose tip, ear lobe) where α1-mediated vasoconstriction can cause ischemic necrosis. In asthma and anaphylactic bronchospasm, nebulized racemic epinephrine (a 1:1 mixture of L- and D-epinephrine) is used for upper airway obstruction from croup and post-extubation stridor, working through α1-mediated mucosal vasoconstriction to reduce subglottic edema. Topical ophthalmic epinephrine reduces intraocular pressure by decreasing aqueous humor production (β2 mechanism) and increasing uveoscleral outflow.45
First-line treatment: epinephrine 0.3–0.5 mg IM into the mid-anterolateral thigh (vastus lateralis), 1:1000 solution (1 mg/mL). Repeat every 5–15 minutes if no response. IV epinephrine only for cardiac arrest or refractory shock with hemodynamic monitoring — avoid IV bolus in awake patients. Subcutaneous injection is inferior to IM for speed of absorption and should not be the preferred route. No absolute contraindications to epinephrine in anaphylaxis.
Norepinephrine is the principal endogenous neurotransmitter of postganglionic sympathetic neurons and the dominant vasopressor in clinical practice for most forms of distributive shock. Its receptor profile differs from epinephrine in one pharmacologically consequential way: norepinephrine has substantially weaker activity at β2 receptors, so it produces predominantly vasoconstriction without the β2-mediated vasodilation and bronchodilation that characterize epinephrine.
Receptor Profile and Hemodynamic Effects. Norepinephrine is a potent full agonist at α1, α2, and β1 receptors, with comparatively weak activity at β2 receptors. At clinical vasopressor doses, systemic α1 activation causes arteriolar and venous vasoconstriction throughout the systemic circulation, increasing systemic vascular resistance (SVR) and both systolic and diastolic blood pressure. Unlike epinephrine, there is no significant β2-mediated vasodilation to counterbalance this effect, so mean arterial pressure (MAP) rises reliably. The increase in afterload produced by α1 vasoconstriction tends to reduce cardiac output unless β1-mediated positive inotropy is sufficient to overcome the added impedance. In patients with preserved ventricular function, the net effect on cardiac output is variable and typically modest. In cardiogenic shock, the increase in afterload can be detrimental. Reflex bradycardia through baroreceptor activation frequently accompanies the pressor response, which may partially offset β1-mediated tachycardia; the net heart rate effect is therefore less predictable than with epinephrine or dobutamine. Coronary blood flow is maintained or improved because the increase in diastolic pressure (the driving pressure for coronary perfusion) offsets the increase in myocardial work.7
Clinical Use in Distributive Shock. Norepinephrine is the vasopressor of first choice for septic shock, supported by multiple randomized controlled trials and surviving sepsis campaign guidelines. The Sepsis Occurrence in Acutely Ill Patients II (SOAP II) trial demonstrated that norepinephrine was associated with fewer arrhythmias and improved survival in the cardiogenic shock subgroup compared with dopamine; the overall 28-day mortality was similar but the adverse event profile favored norepinephrine. Current guidelines recommend initiating norepinephrine rather than dopamine in adult patients with septic shock. The initial infusion rate is typically 0.01 to 0.05 mcg/kg/min, titrated upward to maintain MAP above 65 mmHg (millimeters of mercury), with dose escalation up to 0.5 to 1 mcg/kg/min or higher in refractory cases before adding vasopressin or epinephrine. Norepinephrine is also used in neurogenic shock (loss of sympathetic tone after spinal cord injury), hepatorenal syndrome (to increase renal perfusion pressure), and as an adjunct in other distributive states.78
Adverse Effects and Monitoring. The most clinically significant adverse effects of norepinephrine relate to its vasoconstrictive mechanism. Peripheral ischemia can develop in digits, limbs, and visceral organs during prolonged high-dose infusion, particularly in patients with pre-existing vascular disease or low cardiac output. Mesenteric and hepatic ischemia are recognized complications of high-dose norepinephrine, and monitoring of hepatic function, lactate, and signs of gut ischemia is essential during sustained infusion. Extravasation of norepinephrine from peripheral intravenous access causes severe local tissue necrosis because of intense α1-mediated vasoconstriction; this is treated with local phentolamine (an α-adrenergic antagonist) infiltration, and norepinephrine should ideally be administered through central venous access. Cardiac arrhythmias are less frequent than with dopamine or epinephrine at equivalent vasopressor doses. Rebound hypotension on discontinuation can occur if the infusion is stopped abruptly rather than weaned gradually, particularly after prolonged use.7
If extravasation occurs: stop the infusion immediately, aspirate any residual drug through the existing catheter, then infiltrate the affected area with phentolamine 5–10 mg diluted in 10–15 mL normal saline using a fine-gauge needle. Phentolamine competitively blocks α1 receptors in the skin and subcutaneous tissue, reversing vasoconstriction and preventing ischemic necrosis. Treatment is most effective when started within 12 hours of extravasation. Central venous access for ongoing norepinephrine infusion is preferred to prevent recurrence.
Dopamine is an endogenous catecholamine that serves as the immediate biosynthetic precursor of norepinephrine and as a neurotransmitter in its own right. As an exogenously administered drug, dopamine is characterized by dose-dependent engagement of distinct receptor populations, producing qualitatively different hemodynamic effects across its dose range. This complexity makes it the most pharmacologically nuanced of the commonly used catecholamine vasopressors, and has led to its progressive displacement by norepinephrine in most shock contexts.
Dose-Dependent Receptor Engagement. At low infusion rates (1 to 3 mcg/kg/min), dopamine activates dopamine type-1 (D1) and dopamine type-5 (D5) receptors in the renal and mesenteric vasculature, producing regional vasodilation and natriuresis. At intermediate rates (3 to 10 mcg/kg/min), plasma concentrations are sufficient to activate myocardial β1 receptors directly and to stimulate norepinephrine release from sympathetic nerve terminals through indirect agonist effects, producing positive inotropy and chronotropy with a net increase in cardiac output. At high rates (above 10 mcg/kg/min), α1 receptor activation causes systemic vasoconstriction, increasing systemic vascular resistance (SVR), and the hemodynamic profile increasingly resembles norepinephrine. The threshold plasma concentrations for these effects vary substantially between patients because of differences in receptor density, baseline sympathetic tone, volume status, and the degree of norepinephrine depletion in nerve terminals that occurs during prolonged shock states. The traditional dose-range scheme should therefore be understood as an approximation that guides initial titration, not as a precise pharmacological guarantee.9
Renal Protection: Evidence Against. The low-dose or renal-dose dopamine strategy (1 to 3 mcg/kg/min) was based on the physiological observation that D1 receptor activation produces renal vasodilation and natriuresis. For decades this was translated into clinical practice as a nephroprotective strategy in patients at risk for acute kidney injury (AKI). Multiple randomized controlled trials have definitively refuted this rationale. The ANZICS (Australian and New Zealand Intensive Care Society) dopamine trial (Bellomo 2000), a multicenter placebo-controlled randomized trial in 328 patients with early renal dysfunction, found no difference in peak creatinine, requirement for renal replacement therapy (RRT), or length of intensive care unit (ICU) stay between dopamine and placebo groups. Low-dose dopamine also does not prevent AKI following cardiac surgery, radiocontrast exposure, or other nephrotoxic insults. Current evidence-based practice categorically does not support the use of dopamine for renal protection, and this practice should be considered abandoned.910
Dopamine in Shock States. The Sepsis Occurrence in Acutely Ill Patients II (SOAP II) trial (De Backer 2010) randomized 1679 patients in shock to norepinephrine or dopamine as first-line vasopressor. The primary outcome (28-day mortality) did not differ significantly between groups, but dopamine was associated with a significantly higher rate of arrhythmias (24.1% versus 12.4%) and, in the pre-specified cardiogenic shock subgroup of 280 patients, a significantly higher 28-day mortality. These findings established norepinephrine as the preferred vasopressor for septic shock and undermined the rationale for dopamine in cardiogenic shock. Dopamine retains a limited clinical role in select situations: bradycardia with hypotension where its chronotropic effect is desirable but atropine has failed; and potentially in patients with cardiogenic shock complicated by bradycardia, though this use is now largely supplanted by dobutamine plus norepinephrine combination strategies.810
Adverse Effects. Dopamine has a broad adverse effect profile reflecting its multi-receptor activity across dose ranges. Tachyarrhythmias are the most clinically significant adverse effect, occurring at a higher rate than with norepinephrine and including atrial fibrillation, supraventricular tachycardia (SVT), and ventricular ectopy, particularly at doses above 10 mcg/kg/min. Nausea and vomiting occur at all doses through dopamine type-2 (D2) receptor activation in the chemoreceptor trigger zone (CTZ) of the area postrema. Extravasation causes tissue necrosis by the same α1 mechanism as norepinephrine, and central venous administration is preferred. Prolonged infusion can cause digital or limb ischemia. Dopamine infusion suppresses pituitary hormone secretion (growth hormone, thyroid-stimulating hormone (TSH), prolactin) through central D2 receptor effects, and this neuroendocrine suppression may be clinically relevant during prolonged critical illness. Unlike norepinephrine, dopamine crosses the blood-brain barrier (BBB) and contributes to delirium in intensive care unit (ICU) patients.9
Not recommended as first-line vasopressor for septic shock (norepinephrine preferred, SOAP II trial). Not recommended for renal protection in any clinical context (multiple RCTs show no benefit). Retained indications: bradycardia with hypotension when atropine has failed. Use with caution in patients prone to arrhythmias. Central venous access required. Avoid in patients with pheochromocytoma (risk of catecholamine crisis).
Dobutamine is a synthetic catecholamine developed specifically to provide positive inotropy with minimal vasopressor activity, filling the clinical gap between the non-selective catecholamines and the need for pure cardiac output augmentation. It is not an endogenous compound and was designed by structural modification of isoproterenol to achieve preferential β1 activity while retaining enough β2 effect to avoid the vasoconstriction that limits dopamine at high doses.
Mechanism and Receptor Profile. Dobutamine is a racemic mixture of two enantiomers with complementary receptor activities. The (-)-enantiomer (levo-dobutamine) is an α1 agonist and a potent β1 and β2 agonist; the (+)-enantiomer (dextro-dobutamine) is an α1 antagonist and a potent β1 agonist. The combined result is that the α1 effects of the two enantiomers cancel out, leaving net β1 and modest β2 activity. The predominant clinical effect is therefore positive inotropy and modest positive chronotropy from β1 activation, with mild peripheral vasodilation from β2 activity that reduces afterload and further augments forward flow. Dobutamine has negligible activity at dopaminergic receptors. At standard doses (2.5 to 20 mcg/kg/min), dobutamine increases cardiac output, reduces pulmonary capillary wedge pressure (PCWP), reduces systemic vascular resistance (SVR), and increases heart rate. It does not reliably increase mean arterial pressure (MAP) because the vasodilatory effect offsets part of the cardiac output benefit, making it unsuitable as a sole agent for hypotensive patients.11
Absorption, Distribution, Metabolism, and Excretion. Dobutamine must be administered intravenously because it undergoes extensive first-pass metabolism. The plasma half-life is approximately 2 minutes, comparable to the other catecholamines, making it highly titratable during infusion. Metabolism is primarily by catechol-O-methyltransferase (COMT) to the inactive metabolite 3-O-methyldobutamine, with a minor contribution from conjugation. Renal excretion of metabolites accounts for most elimination. Unlike dopamine, dobutamine does not release norepinephrine from nerve terminals; its inotropic effect is entirely direct. Tachyphylaxis develops with prolonged infusion (beyond 72 hours) due to β1 receptor downregulation, which may necessitate dose escalation over time. This tachyphylaxis limits the use of continuous dobutamine infusions as a long-term strategy in chronic heart failure, and intermittent infusion protocols have been investigated but not proven to offer mortality benefit.11
Clinical Use in Cardiogenic Shock and Acute Decompensated Heart Failure. Dobutamine is the inotropic agent of choice for patients with cardiogenic shock or acute decompensated heart failure (ADHF) with reduced cardiac output who require pharmacological support, particularly when systolic blood pressure is preserved or only modestly reduced (above 90 mmHg). In cardiogenic shock, dobutamine is typically combined with norepinephrine: norepinephrine provides the vasopressor support to maintain perfusion pressure while dobutamine augments forward cardiac output and reduces filling pressures. In ADHF management, dobutamine decreases PCWP (reducing pulmonary congestion) and increases cardiac index, producing hemodynamic improvement that can bridge patients to more definitive interventions (revascularization, device therapy, or cardiac transplantation). Its role is palliative and hemodynamic rather than disease-modifying; continuous dobutamine infusions have not been shown to improve survival in chronic heart failure and may increase mortality by increasing arrhythmia risk in already vulnerable myocardium.12
Pharmacological Stress Testing. Dobutamine stress echocardiography (DSE) is a widely used non-invasive test for diagnosing coronary artery disease (CAD) and assessing myocardial viability in patients who cannot exercise adequately. The dobutamine infusion is started at 5 to 10 mcg/kg/min and increased in increments every 3 minutes to a maximum of 40 to 50 mcg/kg/min; atropine 0.5 to 1 mg IV is added if target heart rate (85% of age-predicted maximum) is not achieved. The test detects CAD by producing wall motion abnormalities in myocardial segments supplied by stenotic coronary arteries, as the increased oxygen demand from β1 stimulation cannot be met during ischemia. Dobutamine also identifies viable but dysfunctional hibernating myocardium: a biphasic response (improved contractility at low dose, then worsening at high dose) indicates viable tissue that may recover function after revascularization. Contraindications to DSE include severe aortic stenosis, uncontrolled hypertension, significant arrhythmias, and recent myocardial infarction.11
Dobutamine: primarily inotropic, reduces afterload (β2 vasodilation), does not reliably raise MAP; use when BP is preserved and the primary problem is low cardiac output. Dopamine: mixed inotropic and vasopressor at intermediate doses; use when both low output and hypotension coexist and sole norepinephrine is insufficient. In practice, norepinephrine plus dobutamine is now preferred over dopamine alone for cardiogenic shock, providing vasopressor support (NE) and inotropy (dobutamine) as independently titratable agents.
The catecholamines interact with several important drug classes through pharmacodynamic and pharmacokinetic mechanisms that can produce life-threatening consequences or, conversely, dramatically alter their clinical utility. These interactions are not theoretical; they arise in anesthesia, emergency medicine, and psychiatry practice and must be anticipated before catecholamines are administered.
Monoamine Oxidase Inhibitors. Monoamine oxidase inhibitors (MAOIs; singular: MAOI) are the most dangerous interaction class for the catecholamines. MAOIs irreversibly inhibit monoamine oxidase type A (MAO-A) and/or monoamine oxidase type B (MAO-B), preventing oxidative catabolism of catecholamines at the nerve terminal and in peripheral tissues. When exogenous catecholamines or indirect sympathomimetics (amphetamines, ephedrine, tyramine from food) are administered to a patient taking an MAOI, the inability to catabolize the excess catecholamine leads to prolonged and exaggerated sympathomimetic effects, potentially producing a hypertensive crisis with severe headache, hypertensive encephalopathy, intracerebral hemorrhage, pulmonary edema, and death. Phenelzine (PHZ), tranylcypromine, and isocarboxazid are irreversible, non-selective MAOIs used in psychiatry; selegiline at low doses is relatively MAO-B selective. Because monoamine oxidase (MAO) inhibition is irreversible, the pharmacodynamic interaction persists for two weeks after MAOI discontinuation (the time required for new MAO enzyme to be synthesized), and catecholamines should be avoided or used with extreme caution for this full washout period. When vasopressors are unavoidable in an MAOI-exposed patient, direct-acting agents at the lowest effective dose, with continuous hemodynamic monitoring, are preferable to indirect-acting agents. Phenylephrine, a pure direct α1 agonist without indirect effects, is the safest vasopressor choice in this context.13
Tricyclic Antidepressants. Tricyclic antidepressants (TCAs; individual drug abbreviated TCA) block the norepinephrine transporter (NET) and the dopamine transporter (DAT), preventing reuptake of catecholamines back into the presynaptic terminal after release. This reuptake blockade causes any administered catecholamine to remain in the synapse or bloodstream longer and at higher effective concentration, amplifying its pharmacodynamic effect. Indirect-acting sympathomimetics (drugs that work by releasing stored catecholamines, such as ephedrine and tyramine) are less effective in patients taking these tricyclic antidepressants (TCAs) because NET blockade reduces catecholamine uptake into the terminal, depleting the releasable pool. Direct-acting catecholamines (epinephrine, norepinephrine, phenylephrine) have enhanced effects in TCA-treated patients (those taking tricyclic antidepressants) because of reduced reuptake clearance. The clinical consequence is that standard doses of these drugs can produce exaggerated and prolonged cardiovascular effects; dose reduction and careful monitoring are required. This interaction is particularly relevant in anesthesia, where TCA-treated patients require careful management of sympathomimetics used for hypotension.13
Volatile Anesthetics. Halogenated volatile anesthetics, particularly halothane (which is now largely obsolete but the classic example), and to a lesser degree sevoflurane, desflurane, and isoflurane, sensitize the myocardium to the arrhythmogenic effects of catecholamines. The mechanism involves slowing of inactivation of cardiac sodium and calcium channels, which increases the window for catecholamine-triggered afterdepolarizations, and direct modification of cardiac β-adrenergic receptor signaling. During halothane anesthesia, the threshold dose of epinephrine required to produce ventricular arrhythmias is substantially reduced compared with an awake patient. For this reason, current practice uses epinephrine in the surgical field at concentrations no higher than 1:100,000 and restricts the total dose during halothane anesthesia; sevoflurane and isoflurane have a more favorable arrhythmia profile in this context.14
Beta-Blockers and Epinephrine in Anaphylaxis. Patients taking non-selective beta-blockers (propranolol, nadolol) present a management challenge in anaphylaxis. Beta-blockade prevents the β2-mediated bronchodilatory and vasodilatory effects of epinephrine while leaving its α1-mediated vasoconstrictive effects unopposed. The result is paradoxical severe hypertension (from unopposed α1 activation) with persistent bronchospasm (as β2 bronchodilation is blocked). In this context, glucagon (1 to 2 mg IV) is the preferred adjunct: glucagon activates its own receptor coupled to Gs, increasing cardiac cAMP independently of β-adrenergic receptors, thereby providing bronchodilation and positive inotropy that bypasses the blocked β receptors. Higher and repeated doses of epinephrine are also typically required, and nebulized ipratropium (a muscarinic antagonist) provides additional bronchodilation through an adrenergic-independent pathway.5
Cocaine and Sympathomimetics. Cocaine blocks NET and DAT, potentiating the effects of catecholamines by the same reuptake inhibition mechanism as TCAs. In cocaine-intoxicated patients presenting with sympathomimetic toxidrome (tachycardia, hypertension, hyperthermia, diaphoresis), administration of additional catecholamines or indirect sympathomimetics can precipitate hypertensive crises and arrhythmias. Beta-blockers are contraindicated in cocaine-associated chest pain and hypertension because of the same unopposed α1 phenomenon described for anaphylaxis: blocking β receptors in a state of catecholamine excess leaves α1 vasoconstriction unopposed, worsening coronary vasospasm and systemic hypertension. Benzodiazepines, phentolamine (non-selective α blocker), and nitrates are the preferred agents for managing cocaine-induced cardiovascular toxicity.14
MAOIs + catecholamines: avoid for 2 weeks after MAOI discontinuation (irreversible enzyme); hypertensive crisis risk; use phenylephrine if vasopressor needed. TCAs + direct catecholamines: enhanced and prolonged effects from reuptake inhibition; reduce doses and monitor carefully. Volatile anesthetics (halothane) + epinephrine: myocardial sensitization to arrhythmias; limit epinephrine dose to 1:100,000 maximum. Non-selective beta-blockers + epinephrine (anaphylaxis): unopposed α1, paradoxical hypertension + bronchospasm; use glucagon 1–2 mg IV, repeat epinephrine, add ipratropium. Cocaine + sympathomimetics: avoid; use benzodiazepines and phentolamine for cardiovascular toxicity.
Goldstein DS. Catecholamines 101. Clin Auton Res. 2010;20(6):331-352.
doi:10.1007/s10286-010-0065-7Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. 2004;56(3):331-349.
doi:10.1124/pr.56.3.1Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942.
doi:10.1210/jc.2014-1498Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill; 2018:191-224.
Simons FE, Ardusso LR, Bilò MB, et al. World Allergy Organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011;4(2):13-37.
doi:10.1097/WOX.0b013e318211496cPerkins GD, Ji C, Deakin CD, et al. A randomized trial of epinephrine in out-of-hospital cardiac arrest. N Engl J Med. 2018;379(8):711-721.
doi:10.1056/NEJMoa1806842Levy B. Bench-to-bedside review: is there a place for epinephrine in septic shock? Crit Care. 2005;9(6):561-565.
doi:10.1186/cc3901De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-789.
doi:10.1056/NEJMoa0907118Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998;78(1):189-225.
doi:10.1152/physrev.1998.78.1.189Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J; ANZICS Clinical Trials Group. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Lancet. 2000;356(9248):2139-2143.
doi:10.1016/S0140-6736(00)03495-4Ruffolo RR Jr. The pharmacology of dobutamine. Am J Med Sci. 1987;294(4):244-248.
doi:10.1097/00000441-198710000-00005O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138(1):78-86.
doi:10.1016/S0002-8703(99)70250-4Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95(4):434-441.
doi:10.1093/bja/aei210Hondeghem LM, Katzung BG. Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. Annu Rev Pharmacol Toxicol. 1984;24:387-423.
doi:10.1146/annurev.pa.24.040184.002131